Insider transactions

EDGAR

ACURA PHARMACEUTICALS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–9 of 9

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-01-02 Filed 2026-01-15SKELLY WILLIAM G Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)50,000——675,989Direct (D) No
F1, F2, F3
  • F1 Represents exchange of restricted stock units.
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F3 Does not include Restricted Stock Units.
Open filing 0001104659-26-004050 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15SKELLY WILLIAM G Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units (2021 Plan) — underlying Common Stock (50,000)
Disposed (D)50,000——0Direct (D) No
F2, F4, F6, F5
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F4 1 - for - 1
  • F6 N/A
  • F5 50,000 Restricted Stock Units were granted on January 2, 2025. 25% of Restricted Stock Units vested on the last day of each of March, June, September and December 2025. Restricted Stock Units are being exchanged on a one for one basis for common stock, in each case upon payment of par value.
Open filing 0001104659-26-004050 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15SKELLY WILLIAM G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units (2021 Plan) — underlying Common Stock (50,000)
Disposed (D)50,000——50,000Direct (D) No
F2, F4, F6, F7
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F4 1 - for - 1
  • F6 N/A
  • F7 50,000 Restricted Stock Units were granted on January 2, 2026. 25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2026, subject to immediate vesting in the event of a change of control and certain other events. Reporting Person may elect to exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2027, or earlier upon a change of control.
Open filing 0001104659-26-004050 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15ROSS GEORGE K Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)50,000——595,903Direct (D) No
F1, F2, F3
  • F1 Represents exchange of restricted stock units.
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F3 Does not include Restricted Stock Units.
Open filing 0001104659-26-004048 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15ROSS GEORGE K Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units (2021 Plan) — underlying Common Stock (50,000)
Disposed (D)50,000——0Direct (D) No
F2, F4, F6, F5
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F4 1 - for - 1
  • F6 N/A
  • F5 50,000 Restricted Stock Units were granted on January 2, 2025. 25% of Restricted Stock Units vested on the last day of each of March, June, September and December 2025. Restricted Stock Units are being exchanged on a one for one basis for common stock, in each case upon payment of par value.
Open filing 0001104659-26-004048 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15ROSS GEORGE K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units (2021 Plan) — underlying Common Stock (50,000)
Disposed (D)50,000——50,000Direct (D) No
F2, F4, F6, F7
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F4 1 - for - 1
  • F6 N/A
  • F7 50,000 Restricted Stock Units were granted on January 2, 2026. 25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2026, subject to immediate vesting in the event of a change of control and certain other events. Reporting Person may elect to exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2027, or earlier upon a change of control.
Open filing 0001104659-26-004048 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15THANGARAJ IMMANUEL Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)50,000——547,647Direct (D) No
F1, F2, F3
  • F1 Represents exchange of restricted stock units.
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F3 Does not include Restricted Stock Units.
Open filing 0001104659-26-004053 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15THANGARAJ IMMANUEL Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units (2021 Plan) — underlying Common Stock (50,000)
Disposed (D)50,000——0Direct (D) No
F2, F4, F6, F5
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F4 1 - for - 1
  • F6 N/A
  • F5 50,000 Restricted Stock Units were granted on January 2, 2025. 25% of Restricted Stock Units vested on the last day of each of March, June, September and December 2025. Restricted Stock Units are being exchanged on a one for one basis for common stock, in each case upon payment of par value.
Open filing 0001104659-26-004053 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-15THANGARAJ IMMANUEL Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units (2021 Plan) — underlying Common Stock (50,000)
Disposed (D)50,000——50,000Direct (D) No
F2, F4, F6, F7
  • F2 Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
  • F4 1 - for - 1
  • F6 N/A
  • F7 50,000 Restricted Stock Units were granted on January 2, 2026. 25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2026, subject to immediate vesting in the event of a change of control and certain other events. Reporting Person may elect to exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2027 or earlier upon a change of control.
Open filing 0001104659-26-004053 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–1 of 1

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Ancora Advisors LLC Partly reported under another manager500 SH0 dollarsUnchanged Prior quarter: 500Open filing 0001446114-26-000020 Filed 2026-11-17 Dispute this row
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

No Schedule 13D or 13G naming this issuer is in the store; this is not a statement that none were filed.

What was read

2,544,215 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020170,508
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to ACURA PHARMACEUTICALS, INC.